I-Mab (IMAB) Q2 2022 Earnings Call Transcript

For the period ending June 30, 2022

August 30, 2022 9:15 a.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Tyler Ehler

This is Tyler Ehler, I-Mab’s Senior Director of Investor Relations. At this time, all participants are in a listen-only mode. At the end of this call, we’ll conduct a Q&A session and instructions will follow at that time. Earlier today, we issued a press release providing a review of our financial results for the six months ended June 30, 2022, as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the Investor Relations portion of our website at ir.i-mabbiopharma.com. Joining me today on the call from I-Mab senior management team are Dr. Jingwu Zang, our Founder, Chairman and Acting CEO; Dr. Andrew Zhu, our President; Mr. John Long, our CFO; and Mr. Richard Yeh, our Chief Operating Officer. Dr. Zang will provide a high level overview of our recent achievements and upcoming milestones while Dr. Andrew Zhu will provide an update on our R&D progress. And finally, Mr. John Long will provide – will then provide a summary of our financial results for the six months ended June 30, 2022.

Before we turn the call over to the operator to take your questions, please note that today’s discussion will contain forward-looking statements relating to the company’s future performance and are intended to qualify for the safe harbor from liability as established by the U.S. Private Securities Litigation Reform Act. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions, and other factors. Some of these risks are beyond the company’s control and could cause actual results to differ materially from those mentioned in today’s press release and this discussion. The general discussion of the risk factors that could affect I-Mab’s business and financial results is included in certain filings of the company with the Securities and Exchange Commission. The company does not undertake any obligation to update this forward-looking information except as required by law. We will also discuss specific non-GAAP financial measures for comparison purposes only during today’s call. Please see the financial results news release issued earlier today for a definition of non-GAAP financial measures and a reconciliation of GAAP to non-GAAP financial results.

With that I’ll now turn the call over to Dr. Jingwu Zang, our Founder, Chairman and Acting CEO. Dr. Zang, please go ahead.